Prostatype Genomics offers prostate cancer patients a decision support for the most optimal treatment option!
We developed a test system called 'Prostatype® Test System'. The system is based on a gene expression test, which measures the expression of three carefully selected embryonic stem cell genes in prostate cancer core needle biopsies. In conjunction with currently used clinical parameters, the PrTS predicts overall survival in relation to treatment.
The Prostatype® Test System helps to choose the optimal treatment strategy for each patient. This secures quality of life for patients with a low risk tumor without jeopardizing safety for patients with aggressive tumors.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Gustav Iii S Boulevard 34, Stockholm,stockholm County 16973,sweden
- Industry
- Medical Equipment Manufacturing
- NAICS
-
Medical Equipment and Supplies ManufacturingSurgical and Medical Instrument ManufacturingSurgical Appliance and Supplies ManufacturingDental Equipment and Supplies ManufacturingOphthalmic Goods ManufacturingDental Laboratories
- Website
- chundsell.com
- HQ
- Stockholm, Stockholm County
Prostatype Genomics Ab Questions
Prostatype Genomics Ab's website is chundsell.com
Prostatype Genomics Ab's LinkedIn profile is https://se.linkedin.com/company/prostatypegenomicsab
Prostatype Genomics Ab has
10 employees.
View email and phone details for 10
employees at Prostatype Genomics Ab.
Prostatype Genomics Ab's industry is
Medical Equipment Manufacturing
Prostatype Genomics Ab's top competitors are
Devyser,
Elypta,
Brice Group,
Life Science Invest Fund,
Navia Corporate Finance,
Lipidor Ab,
Recipharm,
Xspray Pharma Ab (Publ),
Forensic Genomics Innovation Hub,
Base Genomics.
Prostatype Genomics Ab's categories are Medical Equipment Manufacturing
Prostatype Genomics Ab's founding year is 2007
